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Functional or secondary tricuspid regurgitation (STR) is the most frequent etiology of tricuspid valve pathology in
Western countries. Surgical tricuspid repair has been avoided for years, because of the misconception that tri-
cuspid regurgitation should disappear once the primary left-sided problem is treated; this results in a large num-
ber of untreated patients with STR. Over the past few years, many investigators have reported evidence in favor
of a more aggressive surgical approach to STR. Consequently, interest has been growing in the physiopathology
and treatment of STR. The purpose of this review is to explore the anatomical basis, pathophysiology, therapeu-
tic approach, and future perspectives with regard to the management of STR. (J Am Coll Cardiol 2012;59:
703–10) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.069Functional or secondary tricuspid regurgitation (STR) refers
to tricuspid regurgitation (TR) occurring secondary to
left-sided heart disease (LHD) or pulmonary hypertension
in the absence of organic lesions of the tricuspid valve (TV)
apparatus and is the most frequent etiology of TV disease in
Western countries (1). The “functional” label used regarding
TR secondary to pulmonary hypertension or LHD is
possibly a misnomer, in that because of the absence of any
organic pathology, it could be incorrectly interpreted as a
benign condition that would resolve itself after the correc-
tion of the primary disorder.
Therefore, STR is not a truly functional entity, because it
entails intrinsic anatomical abnormalities of the TV appa-
ratus, such as annular dilation and deformation.
Until recently, surgical avoidance of TV repair was easily
accepted in patients with STR, on the basis of the incorrect
concept that TR would disappear once the primary LHD
had been treated (2). The physiopathology and the treat-
ment of this condition have been neglected for a number of
years. This conservative approach still influences surgical
practice today, and TV repair remains an all too infrequent
procedure at most surgical centers. Over the past few years,
many investigators have reported evidence in favor of a more
aggressive surgical approach to STR (3–5). Currently,
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accepted September 5, 2011.moderate to severe TR affects approximately 1.6 million
patients in the United States, of whom only 8,000 undergo
tricuspid surgery annually (6); this results in an extremely
large number of untreated patients with STR.
Significant residual TR has been reported in 10% to 45%
of patients after TV repair with different techniques (7–11).
Consequently, interest has been growing in the physiopa-
thology and treatment of STR. The present report is aimed
at both medical cardiologists and cardiac surgeons, because
their roles in the management of patients with TR are
usually different; generally, it is the cardiac surgeon who
makes the decision concerning whether or not to perform
TV repair during left-heart surgery, while medical cardiol-
ogists are reluctant to recommend reoperative tricuspid
surgery after surgical correction of the LHD that initially
provoked TR, because of the increased morbidity and
mortality associated with reoperative open-heart operations
(12). This review should foster active preoperative and
intraoperative collaboration between cardiologists and sur-
geons in performing TV repair in individual patients.
Anatomy
The orifice of the TV is semilunar in shape because of the
way the right ventricle is wrapped around the left ventricle.
The TV complex (Fig. 1) consists of 3 leaflets (septal,
posterior, and anterior), chordae tendineae, and usually 3
papillary muscles (the anterior, the posterior, and a third
variable papillary muscle). The septal cusp, shaped like part
of a semicircle, has 1 anatomical feature of importance: a
number of third-order chordae tendineae that join the body
of the cusp are attached directly to the septum.
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the TV is normally encircled by
the right coronary artery. Other
structures of major surgical sig-
nificance surrounding the TV are
the coronary sinus, the atrioven-
tricular (AV) node and the bun-
dle of His.
The AV node lies in the atrial
septum bordering the septal leaf-
let. The exact location of the AV
node can be approximated at the
apex of the triangle of Koch,
which is composed of the septal
annulus and the tendon of To-
daro as its sides and the coronary
sinus orifice as its base. Extending from the AV node is the
bundle of His, which penetrates the right trigone under the
interventricular component of the membranous septum.
Along the line of attachment, a fibrous “ring” is not as
easy to define as it is around the mitral valve (MV), although
it remains identifiable.
Compared with the MV, the tricuspid orifice is larger and
more triangular. In physiologic conditions, the tricuspid
annulus (TA) has an elliptic, nonplanar shape. The superior
points of the TA are the anterior and the posterior ones,
while the septal and lateral points are inferior, toward the
right ventricle (13,14).
The nonplanar and noncircular structure of the TA must
be taken into account when considering STR repair; spe-
cifically shaped annular prostheses are currently used for
surgical correction of STR (15).
Pathophysiology of
Secondary Tricuspid Regurgitation
TV closure during systole is a dynamic and complex
mechanism that requires the harmonious interaction of the
whole valve apparatus. The most common etiology of STR
is RV dilation and dysfunction from LHD, as in cases of
MV disease (2,16). Dilated cardiomyopathy and hyperten-
sive pulmonary disease are less frequent causes of STR (2).
The pathophysiology of STR may be divided into 3
phases (17). In the first phase, initial dilation of the right
ventricle results in TA dilation; TR may or may not be
present, depending on the degree of annular dilation (3). In
he second phase, with progressive RV and TA dilation,
ignificant STR occurs because of the failure of leaflet
oaptation (18). Finally, with progressive RV distortion
nd eccentricity, tethering of the leaflets occurs, in
ddition to TA dilation, because of the attachment of the
apillary muscles of the leaflets to the free wall of the
ight ventricle (19).
A dilation and dysfunction. STR is typically associated
ith TA dilation (3). The TA is a component of both the
Abbreviations And
Acronyms
AV  atrioventricular
LHD  left-sided heart
disease
LV  left ventricular
MV  mitral valve
RV  right ventricular
STR  secondary tricuspid
regurgitation
TA  tricuspid annulus
TR  tricuspid
regurgitation
TV  tricuspid valveV and the right ventricle. With gross RV enlargement, theshape of the orifice of the TV becomes much more circular
and prevents normal leaflet coaptation (20). dilation of the
TA occurs mainly in its anterior and posterior portion,
corresponding to the free wall of the right ventricle, while
the dilation of the septal segment is limited because of its
close anatomical relationship with the fibrous skeleton of
the heart (3) (Fig. 2).
There are both differences and similarities between func-
tional tricuspid insufficiency and functional mitral insuffi-
ciency, but the differences are more significant.
The first is that, on the left side, the single anterior leaflet
is the part that moves the most and is the most important
part functionally, because it covers a disproportionately large
area of the orifice in systole. On the right side, however, the
multiple leaflets and scallops of the mural part of the valve
move the most and cover a disproportionately large area of
the orifice in closing (16).
The second difference is that the mitral papillary muscles
arise from the middle of the left ventricle, and their
displacement by ventricular dimension changes is a more
potent source of functional mitral insufficiency than annular
dilation. The tricuspid papillary attachments arise, in the
case of the septal leaflet, directly from the upper septum and
otherwise from extremely variable papillary muscles at-
tached to the trabecular septum. As such, they are very little
affected by dilation of the free RV wall, and lengthening of
the mural annulus is by far the dominant mechanism of
STR (3,16).
RV remodeling and TV tethering. The pathophysiologic
explanation for STR in patients with LHD is rising left
atrial pressure transmitted through the lungs as pulmonary
hypertension (2). This typically causes RV dilation, which
Figure 1 The Tricuspid Valve
Surgical anatomy of the tricuspid valve: the triangle of Koch (TK) is indicated by
the orange area. Ant  anterior; AVN  atrioventricular node; CSO  coronary
sinus orifice; Post  posterior; Sept  septal; TT  tendon of Todaro). Figure
illustration by Craig Skaggs.
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February 21, 2012:703–10 The Tricuspid Valve Revisitedleads to regurgitation by dilation of the TA and subse-
quently by tethering of the TV leaflets (17).
The flattening of the TV annulus that occurs with TA
dilation in STR can potentially alter the normal papillary
muscle-to-leaflet and annulus relationship, because the low
points of the annulus may be stretched away from the
papillary muscles, thereby increasing tethering (20).
Changes in RV geometry and consequent papillary mus-
cle displacement are also critical factors in the pathophysi-
ology of STR, leading to tenting volume enlargement and
inadequate leaflet coaptation (21,22) (Fig. 3).
It is extremely important to bear in mind that once the
TV is dilated, its size cannot spontaneously return to
normal, and it may continue to dilate further. Moreover,
complete reverse remodeling of the right ventricle may not
occur (23).
Pulmonary hypertension. Pulmonary hypertension is not
a necessary prerequisite to developing STR. Fukuda et al.
(24) observed septal leaflet tethering in patients with STR
Figure 2 Tricuspid Annular Dilation
(A) Normal tricuspid valve. (B) Asymmetric dilation and deformation of the tricusp
A  anterior leaflet; P  posterior leaflet; S  septal leaflet.
Figure 3 Tricuspid Valve Tethering
Schematic of the pathophysiology of secondary tricuspid regurgitation secondary
to right ventricular remodeling and leaflet tethering. LV  left ventricle;
RV  right ventricle.Tand normal pulmonary artery pressures. When the septum is
hypokinetic, dyskinetic, or dilated, there can be a tethering
effect on the TV, independently from pulmonary hyperten-
sion, because of the right ventricle’s septal wall, which is the
area of origin of the papillary muscles to the septal leaflet of
the TV (21).
Natural History and Prognostic Implications
Severe TR is an independent predictor of long-term mor-
tality (65% 1-year survival rate in patients with severe TR
compared with 90% of patients without TR) (25). Several
studies reported a higher long-term mortality rate, lower
quality of life, and reduced exercise capacity in patients who
developed severe TR after MV surgery (26,27).
The prevalence of STR in patients with MV disease is
high: 30% of patients with degenerative mitral regurgita-
tion have TR  2 at the time of mitral surgery (28), and
p to one-third of patients with significant mitral stenosis
ave moderate to severe TR (29).
The prevalence of STR is also particularly high in
atients with ischemic mitral regurgitation (30% of
atients who underwent revascularization and MV sur-
ery) (23).
Significant TR occurring late after left-heart surgery is
bserved in up to 40% of patients, with a median survival of
years. An increase of 2 grades in TR with respect to
reoperative echocardiography is reported in about 50% of
atients who undergo isolated MV repair (26,30).
Late TR onset after isolated mitral surgery is associated
ith decreased exercise tolerance and poor quality of life
31). Many of these patients undergo reoperative TV
urgery, with an early mortality rate of 10% to 25% (13).
Tager et al. (32) reported that concomitant TV repair at
he time of MV surgery results in TR resolution in about
5% of patients, while several other groups observed a
igher incidence of post-operative TR in patients in whom
ulus leading to tricuspid regurgitation.id annR was not treated than in patients who underwent TV
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The Tricuspid Valve Revisited February 21, 2012:703–10repair. Therefore, it is almost universally accepted that TV
annuloplasty during mitral surgery results in a lower inci-
dence of late TR.
However, because of the absence of controlled random-
ized trials, it is still debated whether a lower incidence of
late TR after surgery may improve survival and heart failure
symptoms.
Conservative Management
Conservative management of STR includes optimization of
RV preload and afterload. RV overload may benefit from
progressive use of diuretics and angiotensin-converting
enzyme inhibitors. However, an excessive reduction in
central venous pressure may result in worsening of TR
severity (2).
The use of angiotensin-converting enzyme inhibitors is
supported by evidence that chronic RV pressure overload
activates the renin-angiotensin-aldosterone system, which
may contribute to fluid retention and ventricular remodeling
(33); B-type natriuretic peptide is usually increased in cases
of RV pressure or volume overload (34).
Although a causal relationship between TR severity and
more severe renal failure has not been demonstrated, an
association between TR grade and lower estimated glomer-
ular filtration rate, higher blood urea nitrogen, and higher
blood urea nitrogen/creatinine ratio has been described (35).
Surgical Management of
Secondary Tricuspid Regurgitation
The principles of therapy for STR include elimination of
increased afterload to the right ventricle (by correction of
LHD and optimization of left ventricular [LV] function)
and correction of TA dilation and dysfunction, usually by
TV annuloplasty (17).
Current European and U.S. guidelines regarding TV
surgery are reported in Table 1 (36,37).
Annular dilation. TA dilation is invariably associated with
STR (3). Some studies have suggested that concomitant tricuspid
annuloplasty should be performed during left-heart surgery if the
TA is dilated, irrespective of the grade of TR (3,38). Moderate
annular dilation may not be detected by 2-dimensional echo-
cardiography; 3-dimensional echocardiography probably offers
a more accurate assessment (39). Because of the nonplanar
Guidelines for Tricuspid Valve Repair for Secondary TRTable 1 Guidelines for Tricuspid Valve Repair for Secondary TR
European Society of Cardiology (2007)
Class I: severe TR in a patient undergoing left-sided valve surgery (C)
Class IIa moderate TR with dilated annulus (40 mm) in a patient undergoing left-s
Class IIa: symptomatic severe TR late after left-sided valve surgery in the absence
without severe pulmonary hypertension (C)
American College of Cardiology/American Heart Association (2008)
Class I: severe TR in patients undergoing MV surgery (B)
Class IIb: “less than severe TR” in patients undergoing MV surgery, with pulmonarLevels of evidence are shown in parentheses.
MV  mitral valve; TR  tricuspid regurgitation.saddle shape of the TA, there is no echocardiographic stan-
dardized approach to define annular dilation (40,41).
An alternative approach to measuring the TA is direct
intraoperative assessment (3).
Preoperative and intraoperative echocardiography should
determine which patients undergoing MV surgery should
also have tricuspid repair by measuring the TA: tricuspid
repair should be performed in cases of TA 40 mm in the
4-chamber view (42).
Moderate TR. Moderate TR is associated with poorer
long-term survival (4,25,43). Because of the difficulties in
predicting the patients in whom moderate regurgitation will
resolve or progress after left-sided heart surgery, the systematic
repair of a moderately regurgitant TV during MV surgery
should be considered, especially in cases of dilated TA.
The arguments against systematic repair of moderate
STR are that it may resolve after correction of LHD,
prolonged duration of cardiopulmonary bypass and cross-
clamp time, and that annuloplasty may introduce incremen-
tal risks such as AV block (44,45).
Pulmonary hypertension. In cases of TV dysfunction, the
grade of pulmonary hypertension has been shown to be
associated with the severity of TR (20). Pulmonary hyper-
tension may persist after mitral surgery in about 25% of
cases; progressive tricuspid dysfunction may also occur in
unrepaired valves (46). However, isolated pulmonary hyper-
tension in the presence of a normal TV is not considered an
indication for TV repair.
The risk of acutely exposing the right ventricle to increased
afterload after TV repair should be taken into account, espe-
cially in situations in which severe pulmonary hypertension
may persist, because early postoperative RV dysfunction has a
prognostic value after tricuspid surgery (47).
Secondary TR and ischemic mitral regurgitation. Con-
comitant STR is a frequent finding in patients with isch-
emic cardiomyopathy and functional mitral regurgitation
(23). When left untreated, STR progression after surgical
revascularization and mitral surgery in ischemic cardiomy-
opathy negatively affects prognosis (48).
In summary, the aforementioned clinical studies could
lead to general recommendations as to when, or when not,
to correct STR.
Moderate to severe STR should be corrected at the same
time as left-heart surgery (36,37). If severe TV tethering is
alve surgery (C)
t-sided myocardial, valve, or right ventricular dysfunction and
y hypertension or tricuspid annular dilation (C)ided v
of lef
y arter
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February 21, 2012:703–10 The Tricuspid Valve Revisitedpresent (tethering distance 0.76 cm or tethering area
1.63 cm2), the use of adjunctive surgical techniques to
tricuspid annuloplasty or TV replacement should be con-
sidered (7,17). Less than severe STR should be surgically
corrected in cases of concomitant LHD requiring surgery in
the presence of TA dilation (TA 40 mm on preoperative
echocardiography or 70 mm on intraoperative inspection)
(3,38).
In cases of less than severe asymptomatic STR, in the
absence of LHD requiring surgery, conservative manage-
ment and clinical follow-up should be carried out (17).
Surgical Treatment of
Secondary Tricuspid Regurgitation
TV annuloplasty is the basis of current surgical therapy for
STR and aims to correct annular dilation and restore
annular geometry, resulting in improved leaflet coaptation.
Two principal surgical methods are used to treat STR: suture
annuloplasty techniques and the ring annuloplasty techniques.
With suture annuloplasty methods, annular size is re-
duced by using a continuous suture to purse string the
annulus. Most suture annuloplasty techniques are modified
versions of Kay bicuspidization (Figs. 4A and 4B) (49) or
De Vega annuloplasty (Fig. 5A), which consists of the
Figure 4 Kay Repair Technique
(A) Tricuspid valve bicuspidization is accomplished by plicating the annulus
along the posterior leaflet. (B) The sutures are tied, obliterating the posterior
leaflet, creating a bicuspid valve. Figure illustration by Craig Skaggs.plication of both the posterior and anterior annulus (50).With prosthetic ring annuloplasty (Fig. 5B), the annulus
is permanently fixed in a systolic position by suturing in a
rigid or semirigid ring (51).
Recent long-term studies have suggested that prosthetic
ring annuloplasty repair is more durable than suture repair
and confers significant improvements both in overall and
event-free survival. In many series, freedom from moderate
or severe TR 10 years after surgery is85% for patients who
underwent ring annuloplasty (8,52).
The goal of reconstructive valve surgery is to preserve
leaflet mobility and to create a large surface of coaptation,
while preventing further annular dilation.
Figure 5 Other Surgical Tricuspid Repair Techniques
(A) De Vega repair: a single suture is placed around the tricuspid annulus,
avoiding the area of the atrioventricular node. The suture is tied, completing
the annuloplasty. (B) Tricuspid annuloplasty with rigid prosthetic ring: a sizer
measuring the intertrigonal distance is used to determine the ring size. Multi-
ple interrupted sutures are placed at the atrioannular junction. (C) The clover
technique: the middle parts of the free edges of the tricuspid leaflets are
sutured together, producing a clover-shaped valve. Figure illustration by
Craig Skaggs.
C
1
n
w
t
h
T
p
“
f
l
(
r
t
a
(
T
s
f
a
(
a
m
b
F
P
s
d
a
v
a
a
f
b
a
d
A
a
i
n
t
t
a
o
i
s
v
t
p
a
i
c
a
i
a
r
r
r
r
a
w
d
d
m
a
C
T
t
t
708 Taramasso et al. JACC Vol. 59, No. 8, 2012
The Tricuspid Valve Revisited February 21, 2012:703–10The most widely used prosthetic rings in surgical practice
are currently the Carpentier-Edwards annuloplasty ring
(Edwards Lifesciences LLC, Irvine, California), the flexible
band Cosgrove-Edwards annuloplasty system (Edwards
Lifesciences, LLC), and the Edwards MC3 ring system
(Edwards Lifesciences, LLC).
The Carpentier-Edwards ring has been the repair
device of choice for many years. The oval tricuspid ring
conforms to the configuration of the normal tricuspid
orifice and has an opening in the anteroseptal commissure
that allows surgeons to avoid sutures in the area of the
bundle of His. It has a 2-dimensional shape and is
semirigid. Despite its good results (97.5% freedom from
TV reoperation at 10 years) (8), it has been suggested
that the mismatch in configuration between the
Carpentier-Edwards ring and the TA has been respon-
sible for incidental repair failure (15).
In 2002, a new generation of prosthetic ring was intro-
duced. The MC3 ring has adopted the concept of remod-
eling annuloplasty. This ring has a 3-dimensional design
and is preconfigured to best accommodate the saddle shape
of the annulus.
Observational studies have compared the results with the 2
most used tricuspid rings, but no randomized trials have yet
been conducted. Navia et al. (53) reported an incidence of
recurrent TR 3/4 5 years after surgery with the standard
arpentier-Edwards ring and with the MC3 ring of 10% and
4% respectively, but this difference was not statistically sig-
ificant.
Excellent reductions in TR severity early after surgery
ith the MC3 ring have been reported by other investiga-
ors (15). However, in some series, up to 14% of patients
ad significant TR 1 year after surgery: preoperative severe
R and increased leaflet tethering were the most significant
redictors of residual TR (54).
Adjunctive repair techniques include the edge-to-edge
clover” technique (Fig. 5C), which consists of suturing the
ree margins of the leaflets in conjunction with ring annu-
oplasty (55) and anterior tricuspid leaflet augmentation
56). Excellent results with the clover technique were
eported in a recent observational study (57); the combina-
ion of edge-to-edge repair with tricuspid annuloplasty is
ssociated with a very low rate of recurrent significant TR
8.8% at 2 years after surgery) (53).
Risk factors for repair failure included higher preoperative
R severity, higher pulmonary artery pressures, larger ring
ize, MV replacement rather than repair, worse LV dys-
unction, increased LV remodeling, suture annuloplasty,
nd the presence of pacemaker leads through the valve area
7,10,24).
Despite the absence of randomized trials, it is currently
ccepted by the majority of surgeons that ring repairs are
ore durable than suture repairs and are associated withetter long-term and event-free survival (8,10,52,53). tuture Perspectives
ercutaneous procedures may be an attractive alternative to
urgery for patients deemed to be high-risk surgical candi-
ates. Whereas over the past few years, the development
nd clinical use of percutaneous approaches to the aortic
alve and MV have been widespread, few data are available
bout the feasibility and the efficacy of the percutaneous TV
pproach. Some of the concepts that have been developed
or the percutaneous treatment of mitral regurgitation may
e adapted to percutaneous repair of the TV (percutaneous
nnuloplasty, edge-to-edge repair) (58).
Different new devices are currently under preclinical
evelopment: the Millipede system (Millipede, LLC, Ann
rbor, Michigan) involves the placement of a tricuspid
nnular ring with an attachment system via either minimally
nvasive surgical or percutaneous methods to restore the
ative tricuspid annular shape and diameter. It is reposi-
ionable and retrievable before deployment.
The feasibility of the implantation of a valved stent into
he tricuspid position has been described using in vivo
nimal models (59). Iino et al. (60) reported the feasibility
f off-pump transapical tricuspid valved stent implantation
n an acute animal model, using a novel valved stent with a
elf-expandable, superabsorbent polymer to reduce paraval-
ular leakage. Hon et al. (61) described beating-heart
ranscatheter TV implantation to treat a degenerated bio-
rosthesis in tricuspid position through direct transatrial
ccess.
An alternative approach to percutaneous treatment of TV
s the implantation of separate valves in the superior vena
ava and inferior vena cava to prevent damage to the liver
nd other organs (62).
The transcatheter implantation of a bioprosthesis
n the tricuspid position presents challenging issues such
s the large dimension of the TA, the slow flow of the
ight-heart side, and the trabeculated structure of the
ight ventricle (58).
With regard to access, the angulation of the annulus in
elation to the superior vena cava and inferior vena cava
equires careful consideration. Alternatively, transapical RV
ccess may be used, but the RV wall is thinner than the LV
all, and multiple chordae may prevent the advance of the
elivery system (58).
A 3-dimensional finite element model of the TV has been
escribed, which may provide a starting point for the develop-
ent of a predictive tool to evaluate quantitatively TV diseases
nd surgical or percutaneous repair procedures (63).
onclusions
he treatment of STR has long been neglected but is now
he subject of hot debate in the field of heart valve disease
herapies.
Several studies have demonstrated improvements in func-
ional status along with TR grade among patients undergo-
709JACC Vol. 59, No. 8, 2012 Taramasso et al.
February 21, 2012:703–10 The Tricuspid Valve Revisiteding concomitant TV repair during mitral surgery, although
data on survival benefits are equivocal. However, results are
imperfect, possibly because of the complex physiopathology
of the disease and the lack of knowledge. Percutaneous TV
technologies may be useful for a large number of patients
with STR undergoing left-side operations who are at high
risk for open-heart surgery.
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